FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.568,27 +498,47 (+0,84%)
Immuron Limited (IMRN)
| Chiusura precedente | 2,5400 |
| Aperto | 2,5400 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 2,4815 - 2,5400 |
| Intervallo di 52 settimane | 1,4810 - 5,9600 |
| Volume | |
| Media Volume | 934.511 |
| Capitalizzazione | 14,968M |
| Beta (5 anni mensile) | 1,14 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4400 |
| Prossima data utili | 28 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireImmuron achieves record quarterly Travelan® sales
Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplemen
- GlobeNewswire
Immuron achieves record monthly Travelan® sales
Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Immuron previously reported (August 9, 2023) that
- GlobeNewswire
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th. A copy of
